B
Bull
Bull · 25%APM
$2.24
Szenariopreis
$7.000
+0.077 (+1.10%)Zum Schluss
Loading chart…
- High
- 7.490
- Open
- 7.006
- VWAP
- 6.83
- Vol
- 19.51K
- Mkt Cap
- 25.30M
- Low
- 6.000
- Amount
- 133.28K
- EV/EBITDA, TTM
- 0.00
Aptorum Group Limited is a United Kingdom-based clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of therapeutic assets to treat diseases with unmet medical needs, particularly in oncology (including orphan oncology indications) and infectious diseases. Its lead projects are ALS-4, SACT-1 and PathsDx Test. ALS-4 is a small drug molecule which appears to target the products produced by bacterial genes that facilitate the successful colonization and survival of the bacterium in the body or that cause damage to the body's systems. SACT-1 is the first repurposed drug candidate to be developed under the Smart-ACT drug discovery platform. The Company's pipeline is also enriched through the co-development of PathsDx Test, a molecular-based rapid pathogen identification and detection diagnostics technology, with Accelerate Technologies Pte Ltd, the commercialization arm of the Singapore's Agency for Science, Technology and Research.
AI analysis of Aptorum Group Ltd (APM)
holdAPM is not a good buy right now for a beginner long-term investor with $50,000-$100,000. The stock lacks strong bullish confirmation, has bearish technical structure, no recent news catalyst, and no supportive proprietary trading signal. Based on the current data, the best direct view is to hold off rather than buy now.
Bewertungskennzahlen
The current forward P/E ratio for Aptorum Group Ltd (APM) is 0.00, compared to its 5-year average forward P/E of -0.89.
Alphio AI Price Scenarios for APM
Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.
Whales holding APM
Event-Zeitleiste
News
8.507-16NewsfilterAptorum Group to Rebrand as Niki BioSolutions Post-Merger
9.503-25Yahoo FinanceAndean Precious Metals Reports Record Revenue and EBITDA for 2025
7.003-06seekingalphaAptorum Group Receives Nasdaq Compliance Notification
- 7.003-06Newsfilter
Aptorum Group Receives Nasdaq Non-Compliance Notification
8.501-20GlobenewswireAndean Precious Metals Corp. Raises C$83.1M by Selling 7.9M Shares at C$10.50 Each
APM FAQ — answered by Alphio AI
Aptorum Group Limited is a United Kingdom-based clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of therapeutic assets to treat diseases with unmet medical needs, particularly in oncology (including orphan oncology indications) and infectious diseases. Its lead projects are ALS-4, SACT-1 and PathsDx Test. ALS-4 is a small drug molecule which appears to target the products produced by bacterial genes that facilitate the successful colonization and survival of the bacterium in the body or that cause damage to the body's systems. SACT-1 is the first repurposed drug candidate to be developed under the Smart-ACT drug discovery platform. The Company's pipeline is also enriched through the co-development of PathsDx Test, a molecular-based rapid pathogen identification and detection diagnostics technology, with Accelerate Technologies Pte Ltd, the commercialization arm of the Singapore's Agency for Science, Technology and Research. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).
APM is not a good buy right now for a beginner long-term investor with $50,000-$100,000. The stock lacks strong bullish confirmation, has bearish technical structure, no recent news catalyst, and no supportive proprietary trading signal. Based on the current data, the best direct view is to hold off rather than buy now.
Diese Seite dient nur der Recherche und ist keine Anlageberatung. Modelle können falsch liegen. Vergangene Wertentwicklung ist kein Indikator für die Zukunft.